

**⑫**

**EUROPEAN PATENT APPLICATION**

**⑲** Application number: **84106363.9**

**⑥①** Int. Cl.<sup>3</sup>: **C 07 C 103/52**  
**A 61 K 37/02**

**⑳** Date of filing: **04.06.84**

**③①** Priority: **06.06.83 US 501321**

**④③** Date of publication of application:  
**12.12.84 Bulletin 84/50**

**⑧④** Designated Contracting States:  
**AT BE CH DE FR GB IT LI LU NL SE**

**⑦①** Applicant: **ADMINISTRATORS OF THE TULANE**  
**EDUCATIONAL FUND**  
**St. Charles Avenue**  
**New Orleans Louisiana 70118(US)**

**⑦②** Inventor: **Coy, David Howard**  
**4319 Perrier Street**  
**New Orleans Louisiana 70115(US)**

**⑦③** Inventor: **Murphy, William Andrew**  
**601 West Hall Avenue**  
**Slidell Louisiana 70458(US)**

**⑦④** Representative: **Wächtershäuser, Günter, Dr.**  
**Tal 29**  
**D-8000 München 2(DE)**

**⑤④** Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith.

**⑥⑦** Novel cyclic pentapeptide somatostatin antagonists and method for increasing the release of growth hormone, insulin, and glucagon in mammals are described.

-1-

CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN  
ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH

The invention herein described relates to novel cyclic pentapeptide somatostatin antagonists and method for increasing the release of growth hormone, insulin, and glucagon in mammals therewith.

5 Mammalian somatostatin, which has the following tetradecapeptide sequence:

H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Try-Lys-Thr-Phe-Thr-Ser-Cys-OH  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 ,

10

inhibits the release of growth hormone from the pituitary and insulin and glucagon from the pancreatic islet cells. It also has inhibitory actions on numerous other endocrine and gastrointestinal activities in mammals. These inhibitory effects are well documented (c.f., P. Brazeau *et al.*, Science 179: 77-79, (1973); W. A. Mortimer *et al.*, Lancet 1: 697-701, (1974), and C. A. Meyers *et al.*, in Gastrointestinal Hormones, edited by G. B. J. Glass, New York: Raven Press, 15 1980, pages 363-385, and their importance to the life cycle of mammals is clearly recognized.

20


25

Although hundreds of somatostatin analogs have been synthesized and evaluated in an attempt to find agonists, antagonists or competitive inhibitors of said hormone, no entirely satisfactory somatostatin antagonist or competitive inhibitor of this hormone has been available or disclosed in the art.


It is, therefore, an object of the present invention to provide a novel somatostatin antagonist effective for increasing release of growth hormone, insulin, and glucagon in mammals.

Surprisingly, this objective has been achieved with the synthesis of cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)], and derivatives and pharmaceutically acceptable salts thereof.

The novel somatostatin antagonists of this invention are cyclic pentapeptides depicted by formula (I) and the pharmaceutically acceptable salts thereof, having the following amino acid sequence:




wherein X is phenylalanyl, tyrosyl, tryptophyl, 4-chlorophenylalanyl, 4-bromophenylalanyl, 4-fluorophenylalanyl, histidyl, 5-fluorotryptophyl, 5-chlorotryptophyl, 5-bromotryptophyl, 5-methoxytryptophyl, 5-methyltryptophyl, 4-methoxyphenylalanyl, 4-benzyloxyphenylalanyl, 4-methylphenylalanyl, or



Y is D-tryptophyl, D-phenylalanyl, D-4-chlorophenyl-  
 alanyl, D-4-bromophenylalanyl, D-4-fluorophenylalanyl,  
 5 D-4-methoxyphenylalanyl, D-4-benzyloxyphenylalanyl,  
D-4-methylphenylalanyl, D-tyrosyl, D-5-fluorotryptophyl,  
D-5-bromotryptophyl, D-5-chlorotryptophyl, D-5-methoxy-  
 tryptophyl, D-5-methyltryptophyl or D-histidyl; Z is  
 lysyl or arginyl; Thr is threonyl and R<sub>1</sub> is hydrogen,  
 10 benzyl or substituted benzyl, connected to the threonyl  
 amino acid residue through its 3-oxygen atom.

The R<sub>1</sub> group referred to above may thus be  
 illustrated as follows:

15



20


wherein R<sub>2</sub> is hydrogen, halogen (including fluorine,  
 chlorine, bromine and iodine, C<sub>1</sub>-C<sub>4</sub> alkoxy (preferably  
 methoxy) or C<sub>1</sub>-C<sub>4</sub> alkyl (preferably methyl).

25

Preferred compounds of the invention have the  
 formula (I) structure wherein R<sub>1</sub> is hydrogen or benzyl;  
 Z is lysyl, and X and Y represent chiral amino acid  
 residues selected from those described for X and Y  
 above.

30

An especially preferred cyclic pentapeptid somatostatin antagonist of this invention is the cyclo[Pro-Phe-D-Trp-Lys-Thr(R<sub>1</sub>)] which may be illustrated as follows:



wherein Phe is phenylalanyl; D-trp is D-tryptophyl; Lys is lysyl; Thr is threonyl, and R<sub>1</sub> is hydrogen or benzyl.

The term "pharmaceutically acceptable salts," as used in the present specification, is intended to mean non-toxic acid addition salts which are commonly used in the pharmaceutical industry. Among those of particular interest in the present invention are the hydrochloride, phosphate, sulfate, laurate, citrate, gluconate, succinate; acetate, and oleate salts of the formula (I) compounds. These salts are readily prepared by methods well known in the art.

In keeping with standard nomenclature, abbreviations for chiral amino acid residues used in the present specification and claims are as follows:

<u>Abbreviation</u>		<u>Name</u>
Phe	=	<u>L</u> -phenylalanyl
Tyr	=	<u>L</u> -tyrosyl
Trp	=	<u>L</u> -tryptophyl
(4-Cl)Phe	=	<u>L</u> -4-chlorophenylalanyl
(4-Br)Phe	=	<u>L</u> -4-bromophenylalanyl
(4-F)Phe	=	<u>L</u> -4-fluorophenylalanyl
His	=	<u>L</u> -histidyl

	<u>Abbreviation</u>		<u>Name</u>
	(4-CH <sub>3</sub> )Phe	=	<u>L</u> -4-methylphenylalanyl
	(4-CH <sub>3</sub> O)Phe	=	<u>L</u> -4-methoxyphenylalanyl
	(4-Bzl-O)Phe	=	<u>L</u> -4-benzyloxyphenylalanyl
5	(5-F)Trp	=	<u>L</u> -5-fluorotryptophyl
	(5-Cl)Trp	=	<u>L</u> -5-chlorotryptophyl
	(5-Br)Trp	=	<u>L</u> -5-bromotryptophyl
	(5-CH <sub>3</sub> O)Trp	=	<u>L</u> -5-methoxytryptophyl
	(5-CH <sub>3</sub> )Trp	=	<u>L</u> -5-methyltryptophyl
10	<u>D</u> -(4-F)Phe	=	<u>D</u> -4-fluorophenylalanyl
	<u>D</u> -(4-Cl)Phe	=	<u>D</u> -4-chlorophenylalanyl
	<u>D</u> -(4-Br)Phe	=	<u>D</u> -4-bromophenylalanyl
	<u>D</u> -(4-CH <sub>3</sub> )Phe	=	<u>D</u> -4-methylphenylalanyl
	<u>D</u> -(4-CH <sub>3</sub> O)Phe	=	<u>D</u> -4-methoxyphenylalanyl
15	<u>D</u> -(4-Bzl-O)Phe	=	<u>D</u> -4-benzyloxyphenylalanyl
	<u>D</u> -Phe	=	<u>D</u> -phenylalanyl
	<u>D</u> -Tyr	=	<u>D</u> -tyrosyl
	<u>D</u> -Trp	=	<u>D</u> -tryptophyl
	<u>D</u> -(5-F)Trp	=	<u>D</u> -5-fluorotryptophyl
	<u>D</u> -(5-Br)Trp	=	<u>D</u> -5-bromotryptophyl
20	<u>D</u> -(5-Cl)Trp	=	<u>D</u> -5-chlorotryptophyl
	<u>D</u> -(5-CH <sub>3</sub> O)Trp	=	<u>D</u> -5-methoxytryptophyl
	<u>D</u> -(5-CH <sub>3</sub> )Trp	=	<u>D</u> -5-methyltryptophyl
	<u>D</u> -His	=	<u>D</u> -histidyl
25	Lys	=	<u>L</u> -lysyl
	Arg	=	<u>L</u> -arginyl
	Ala	=	<u>L</u> -alanyl
	Gly	=	<u>L</u> -glycyl
	Cys	=	<u>L</u> -cysteiny
30	Asn	=	<u>L</u> -asparginyl
	Ser	=	<u>L</u> -seryl
	Pro	=	<u>L</u> -prolyl

Other abbreviations used in the present specification are:

	Bzl	=	benzyl
	FMOC	=	fluorenylmethyloxycarbonyl
	Boc	=	<u>t</u> -butyloxycarbonyl
5	HPLC	=	high performance liquid chromatography
	TFA	=	trifluoroacetic acid
	TLC	=	thin-layer chromatography

10 In accordance with the process of the present invention, solid-phase synthesis of the formula (I) peptides can be carried out on a Beckman 990 automatic peptide synthesizer. Preparative HPLC can be performed on a thick-walled glass column (2.5 x 45 cm) containing  
15 Whatman LRP-1 reverse phase packing (C<sub>18</sub> silica 13-20  $\mu$ m) pumped with Fluid Metering Company pump and pulse damper; and amino acid analyses can be run on a Beckman 119 CL analyzer and processed with a System AA computing integrator.


20 Amino acid derivatives utilized in the preparation of the compounds of the present invention are available from several chemical supply houses including: Bachem, Inc., Torrance, California; and Chemical Dynamics, Inc., Plainfield, New Jersey.

25 Conveniently, the formula (I) peptides of this invention, cyclo[Pro-(X)-(Y)-(Z)-Thr-R<sub>1</sub>], can be prepared beginning with the appropriate  $\alpha$ -amino protected amino acid coupled to an appropriate resin, such as a polystyrene resin with one-two percent by weight of  
30 divinyl benzene as a cross-linking agent.

Protecting groups for the amino acids include: t-butyloxycarbonyl, isopropyloxycarbonyl, diisopropyl-oxycarbonyl, benzyloxycarbonyl, cyclopentyloxycarbonyl, and the like; but, t-butyloxycarbonyl or isopropyloxy-carbonyl are generally preferred.

5 In the process, Fmoc-(Z)-[Boc-Thr(Bzl)]-Pro-(X)-(Y)-O-CH<sub>2</sub>-resin is prepared beginning with the appropriate Boc-(Y)-Merrifield resin, where Y is D-Trp, D-Phe, D-Tyr, D-(5-F)Trp, D-(5-Br)Trp, D-(5-Cl)Trp, D-(5-OCH<sub>3</sub>)Trp, D-(5-CH<sub>3</sub>)Trp, D-(4-F)Phe, D-(4-Cl)Phe, D-  
10 4-Br)Phe, D-(4-CH<sub>3</sub>)Phe, D-(4-CH<sub>3</sub>O)Phe, D-(4-Bzl-O)Phe, or D-His. The resin is placed in the reaction vessel of the peptide synthesizer which has been programmed to carry out the following work-wash cycle: (a) methylene chloride, (b) 33% TFA in methylene chloride, (c)  
15 methylene chloride, (d) ethyl alcohol, (e) methylene chloride, (f) 10% triethylamine in methylene chloride, and (g) methylene chloride.

The washed resin with the Boc group removed is then stirred with t-Boc-(X), where X is Phe, Tyr, Trp, (4-Cl)Phe, (4-Br)Phe, (4-F)Phe, (4-CH<sub>3</sub>)Phe, (4-CH<sub>3</sub>O)-  
20 Phe, (4-Bzl-O)Phe, (5-F)Trp, (5-Cl)Trp, (5-Br)Trp, (5-CH<sub>3</sub>O)Trp, (5-CH<sub>3</sub>)Trp, His or




30



and diisopropylcarbodiimide in methylene chloride. The protected attached amino acids are then cycled through steps (b) through (g) in the above wash program. Thereafter, the following amino acids are coupled by the same cycle of events: t-Boc-Pro, t-Boc-Thr( $R_1$ ) and FMOC-(Z)-Boc, wherein  $R_1$  is benzyl or substituted benzyl, and Z is Lys or Arg. These steps provide the FMOC-(Z)Boc-Thr( $R_1$ )-Pro-(X)-(Y)-O-CH<sub>2</sub>-resin. Removal of the protected peptide from the resin by treatment with a ten-fold excess of hydrazine in methanol is accompanied by loss of the base-sensitive FMOC group to give H(Z)Boc-Thr( $R_1$ )-Pro-(X)-(Y)NHNH<sub>2</sub>, which is cyclized with hydrochloric acid and isoamyl nitrite to give cyclo[Pro-(X)-(Y)-(Z)-Boc-Thr( $R_1$ )]. Treatment of this peptide with 90% TFA in water containing 1% ethanedithiol then yields the desired somatostatin antagonist of this invention cyclo[Pro-(X)-(Y)-(Z)-Thr( $R_1$ )]. These reactions are graphically illustrated in the Flow Diagram I below:

FLOW DIAGRAM I




Alternatively, the compounds of this invention may also be prepared by the process hereinafter described.

After conventional solid-phase assembly beginning with 1 mmole of Boc-Phe-Merrifield resin (1% cross-linked), the protected peptide hydrazide, H-D-Trp-Lys(Cl-Z)-Thr(Bzl)-Pro-Phe-NHNH<sub>2</sub>, is cleaved from the support by treatment with hydrazine in methanol and isolated by a procedure described by D. F. Veber *et al.*, Proceedings of the National Academy of Science, U.S.A., 75: 2636-2640, (1978). Without further purification, the hydrazide is converted to the azide, neutralized with triethylamine, and cyclized in DMF solution to yield the protected ninhydrin negative material, cyclo[Pro-Phe-D-Trp-Lys-(Cl-Z)-Thr(Bzl)]. When this protected ninhydrin negative material is hydrogenated at atmospheric pressure and room temperature over 10% Pd on charcoal, the compound, cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)], is formed and found to be a very effective somatostatin antagonist. When, however, the protected crude ninhydrin negative material is deprotected by treatment with HF-anisole under standard conditions, as described by G. T. Engberg *et al.*, Nature, 293: 222-223, (1981), and purified by preparative HPLC eluting with 10-55% gradient of CH<sub>3</sub>CN in 20% AcOH, the reaction yields the pure peptide, cyclo(Pro-Phe-D-Trp-Lys-Thr), which has somatostatin antagonist activity.

It is also found that HF treatment of the active somatostatin antagonist, cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)], converts it to the peptide, cyclo(Pro-Phe-D-Trp-Lys-Thr), which also has somatostatin antagonist activity. The above reactions are graphically illustrated in Flow Diagram II below.

FLOW DIAGRAM II



20 Among the cyclic pentapeptides of the present invention that display somatostatin antagonism and can be prepared by the process described and illustrated in Flow Diagram II above, are:

- 25 Cyclo[Pro-Phe-D-Tyr-Arg-Thr(Bzl)];
- Cyclo[Pro-His-D-(5-F)Trp-Lys-Thr(Bzl)];
- Cyclo[Pro-(4-F)Phe-D-Trp-Lys-Thr(3-F-Bzl)];
- Cyclo[Pro-Phe-D-(5-CH<sub>3</sub>)Trp-Lys-Thr(Bzl)];
- Cyclo[Pro-Tyr-D-Tyr-Lys-Thr(Bzl)];
- Cyclo[Pro-Phe-D-His-Lys-Thr(Bzl)];
- 30 Cyclo[Pro-Trp-D-Phe-Arg-Thr(Bzl)];
- Cyclo[Pro-(4-Br)Phe-D-(5-Br)Phe-Lys-Thr(Bzl)];
- Cyclo[Pro-Tyr-D-His-Lys-Thr(Bzl)];
- Cyclo[Pro-Tyr-D-His-Arg-Thr(Bzl)];
- 35 Cyclo[Pro-Trp-D-Tyr-Lys-Thr(3-CH<sub>3</sub>-Bzl)];

- Cyclo[Pro-Phe-D-(4-F)Phe-Lys-Thr(Bzl)];  
Cyclo[Pro-Phe-D-(4-Cl)Phe-Lys-Thr(Bzl)];  
Cyclo[Pro-Phe-D-(4-Br)Phe-Lys-Thr(Bzl)];  
Cyclo[Pro-Phe-D-(4-CH<sub>3</sub>)Phe-Lys-Thr(Bzl)];  
Cyclo[Pro-Phe-D-(4-CH<sub>3</sub>O)Phe-Lys-Thr(Bzl)];  
5 Cyclo[Pro-Phe-D-(4-Bzl-O)Phe-Lys-Thr(Bzl)];  
Cyclo[Pro-(4-Me)Phe-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-(4-CH<sub>3</sub>O)Phe-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-(4-Bzl-O)Phe-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)];  
10 Cyclo[Pro-Phe-D-Trp-Arg-Thr(Bzl)];  
Cyclo[Pro-Phe-D-Trp-Lys-Thr(4-Cl-Bzl)];  
Cyclo[Pro-Phe-D-Trp-Lys-Thr(4-OCH<sub>3</sub>-Bzl)];  
Cyclo[Pro-Phe-D-Trp-Lys-Thr(4-CH<sub>3</sub>-Bzl)];  
Cyclo[Pro-Phe-D-Trp-Arg-Thr(3-Br-Bzl)];  
15 Cyclo[Pro-Tyr-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-Trp-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-(4-Cl)Phe-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-(4-F)Phe-D-Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-His-D-Tyr-Lys-Thr(Bzl)];  
20 Cyclo[Pro-Trp-D-(5-OCH<sub>3</sub>)Trp-Lys-Thr(Bzl)];  
Cyclo[Pro-(4-Cl)Phe-D-Tyr-Arg-Thr(4-OCH<sub>3</sub>-Bzl)];  
Cyclo[Pro-Phe-D-Phe-Lys-Thr(Bzl)];  
Cyclo[Pro-His-D-Phe-Lys-Thr(4-Cl-Bzl)];  
Cyclo[Pro-Phe-D-(5-OCH<sub>3</sub>)Trp-Lys-Thr(Bzl)], and  
25 Cyclo[Pro-(4-Br)Phe-D-Tyr-Arg-Thr(Bzl)].

Cyclo(Pro-Phe-D-Tyr-Arg-Thr);  
Cyclo[Pro-His-D-(5-F)Trp-Lys-Thr];  
Cyclo[Pro-Phe-D-(5-CH<sub>3</sub>)Trp-Lys-Thr];  
Cyclo(Pro-Tyr-D-Tyr-Lys-Thr);  
Cyclo(Pro-Phe-D-His-Lys-Thr);  
5 Cyclo(Pro-Trp-D-Phe-Arg-Thr);  
Cyclo[Pro-(4-Br)Phe-D-(5-Br)Phe-Lys-Thr];  
Cyclo(Pro-Tyr-D-His-Lys-Thr);  
Cyclo(Pro-Tyr-D-His-Arg-Thr);  
Cyclo[Pro-Phe-D-(4-F)Phe-Lys-Thr];  
10 Cyclo[Pro-Phe-D-(4-Cl)Phe-Lys-Thr];  
Cyclo[Pro-Phe-D-(4-Br)Phe-Lys-Thr];  
Cyclo[Pro-Phe-D-(4-CH<sub>3</sub>)Phe-Lys-Thr];  
Cyclo[Pro-Phe-D-(4-CH<sub>3</sub>O)Phe-Lys-Thr];  
Cyclo[Pro-Phe-D-(4-Bzl-O)Phe-Lys-Thr];  
15 Cyclo[Pro-(4-Me)Phe-D-Trp-Lys-Thr];  
Cyclo[Pro-(4-CH<sub>3</sub>O)Phe-D-Trp-Lys-Thr];  
Cyclo[Pro-(4-Bzl-O)Phe-D-Trp-Lys-Thr];  
Cyclo(Pro-Phe-D-Trp-Lys-Thr);  
Cyclo(Pro-Phe-D-Trp-Arg-Thr);  
20 Cyclo(Pro-Tyr-D-Trp-Lys-Thr);  
Cyclo(Pro-Trp-D-Trp-Lys-Thr);  
Cyclo[Pro-(4-Cl)Phe-D-Trp-Lys-Thr];  
Cyclo[Pro-(4-F)Phe-D-Trp-Lys-Thr];  
Cyclo(Pro-His-D-Tyr-Lys-Thr);  
25 Cyclo[Pro-Trp-D-(5-OCH<sub>3</sub>)Trp-Lys-Thr];  
Cyclo(Pro-Phe-D-Phe-Lys-Thr);  
Cyclo[Pro-Phe-D-(5-OCH<sub>3</sub>)Trp-Lys-Thr], and  
Cyclo[Pro-(4-Br)Phe-D-Tyr-Arg-Thr].

30

The compounds of formula (I) are useful as somatostatin antagonists and are effective for increasing the release of growth hormone, insulin, and glucagon, in mammalian hosts, when administered thereto at dosages of from 0.000002 to 1 mg/kg of mammalian body weight per day.

The formula (I) compounds may be administered orally in the form of a feed additive or as a bolus, pill, tablet, oral gel, or the like, designed to deliver the active compound at the dosage level desired. They may also be administered parenterally by intramuscular, subcutaneous, intraperitoneal or intravenous injection, or as a transdermal or nasal spray.

As will hereinafter be shown, injection of formula (I) peptide into rats blocks the inhibitory effects of exogenous somatostatin on growth hormone, insulin, and glucagon release. In practice, it is also found that in fasted rats, basal hepatic portal insulin and glucagon levels are significantly increased after treatment with cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)]; and, further, that plasma growth hormone levels in NEMBUTAL®-anesthetized and stimulated rats are increased after injection with the above-said compound.

The following examples further illustrate the present invention, but are not intended to be limitative thereof.

NEMBUTAL® sodium pentobarbital is a product of Abbott Laboratories.

EXAMPLE 1Preparation of N<sup>α</sup>-fluorenylmethyloxycarbonyl-N<sup>ε</sup>-tert-butyloxycarbonyl-L-lysyl-O-benzyl-L-threonyl-L-protyl-L-phenylalanyl-D-tryptophyl-O-CH<sub>2</sub> resin

5                    t-Butyloxycarbonyl-D-tryptophan-Merrifield resin (1% cross-linked, 2.5 g, 1.0 mmole) is placed in the reaction vessel of a Beckman Model 990 automatic peptide synthesizer programmed to carry out the following work-wash cycle: (a) CH<sub>2</sub>Cl<sub>2</sub>; (b) 33% trifluoroacetic acid in  
10 CH<sub>2</sub>Cl<sub>2</sub> (two times for one and 25 minutes each); (c) CH<sub>2</sub>Cl<sub>2</sub>; (d) C<sub>2</sub>H<sub>5</sub>OH; (e) CH<sub>2</sub>Cl<sub>2</sub>; (f) 10% (C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> (two times for two minutes each); (g) CH<sub>2</sub>Cl<sub>2</sub>.

                  The washed resin with the t-butyloxycarbonyl (Boc) group removed is stirred with t-butyloxycarbonyl-phenylalanine (t-Boc-Phe) and diisopropylcarbodiimide  
15 (3 mmole) in CH<sub>2</sub>Cl<sub>2</sub> for one hour and the resulting amino acid resin then washed with CH<sub>2</sub>Cl<sub>2</sub>. The protected, attached amino acids are then cycled through steps (b) through (g) in the above wash program. The following  
20 amino acids (3 mmole) are then coupled successively by the same treatment cycle: t-butyloxycarbonyl-prolyl (t-Boc-Pro); t-butyloxycarbonyl-threonyl-benzyl [t-Boc-Thr(Bzl)] and fluorenylmethyloxycarbonyl-lysyl-t-butyloxycarbonyl [FMOC-Lys(Boc)].

25                    Upon completion of the last coupling reaction, the resulting resin is washed with methanol to obtain the above-identified resinated product.

EXAMPLE 2Preparation of N $\epsilon$ -tert-butyloxycarbonyl-L-lysyl-O-benzyl-L-threonyl-L-prolyl-L-phenylalanyl-D-tryptophyl-NHNH<sub>2</sub>

5 N $\alpha$ 9-fluorenylmethyloxycarbonyl-N $\epsilon$ -tert-butyloxycarbonyl-L-lysyl-O-benzyl-L-threonyl-L-prolyl-L-phenylalanyl-D-tryptophyl-O-CH<sub>2</sub> resin (1.87 g, 0.5 mmol) is suspended in 70 ml of dry methanol and the thus prepared suspension then treated with 7 ml of anhydrous hydrazine. The mixture is stirred for 24 hours at ambient temperature and then filtered, washed with  
10 methanol and the methanol extracts evaporated to yield an oil that solidified upon tritoraction with ether to give 0.65 g of the above-named product in the form of a white powder.

EXAMPLE 3

15 Preparation of cyclo(L-prolyl-L-phenylalanyl-D-tryptophyl-N $\epsilon$ -tert-butyloxycarbonyl-L-lysyl-O-benzyl-L-threonyl)

The peptide hydrazide N $\epsilon$ -tert-butyloxycarbonyl-L-lysyl-O-benzyl-L-threonyl-L-prolyl-L-phenylalanyl-D-tryptophyl-NHNH<sub>2</sub> (0.3 g, 0.33 mmol) is dissolved in  
20 10 ml of dry dimethylformamide (DMF) and cooled to -35°C. The solution is then acidified to pH 1.5 with hydrochloric acid in tetrahydrofurfuryl alcohol (HCl/THF) and isoamyl nitrite (67  $\mu$ l). The mixture is  
25 stirred at -35°C for 45 minutes and then added to 1.5 ml of dimethylformamide (DMF) and cooled to -25°C. The reaction mixture is then neutralized to pH 7.5 with diisopropylethylamine and maintained at -25°C for 24 hours and 5°C for an additional 24 hours. Evaporation  
30 of the DMF gives the above-identified product as a brown oil that exhibits a major spot by thin-layer chromatography (tlc).



EXAMPLE 4Preparation of cyclo(L-prolyl-L-phenylalanyl-D-tryptophyl-L-lysyl-O-benzyl-L-threonyl)

The fully protected peptide cyclo(L-prolyl-L-phenylalanyl-D-tryptophyl-N<sup>ε</sup>-tert-butyloxycarbonyl-L-lysyl-O-benzyl-L-threonyl) is dissolved in 50 ml of a mixture of trifluoroacetic acid, water, and 1,2-ethanedithiol prepared in a ratio of 45:5:2 by volume. The solution is stirred at ambient temperature for 40 minutes and then evaporated to an oil. The resulting oil is dissolved in 50% acetic acid and eluted on a column (2.5 x 95 cm) of Sephadex G-15 with 50% acetic acid. Lyophilized material from a major peak absorbing at 280 nm is then applied to a column of Whatman LRP-1 octadecylsilanesilica and eluted with a linear gradient of 10 to 15% acetonitrile in 20% acetic acid solution.

The major peak is collected and lyophilized to give the required peptide as a white, fluffy powder (90 mg). This material gives one Cl-starch, ninhydrin and Ehrlich reagent-positive spot with the following R<sub>f</sub>'s on silica gel TLC plates: n-BuOH:AcOH:H<sub>2</sub>O:EtOAc (1:1:1:1), 0.68; n-BuOH:AcOH:H<sub>2</sub>O (4:1:1), 0.47; EtOAc:pyridine:AcOH:H<sub>2</sub>O (5:5:1:3), 0.79; 2-PrOH:1MAcOH (2:1), 0.61. Amino acid analysis of a sample hydrolyzed in methanesulfonic acid containing 0.1% tryptamine gives: Thr, 0.98; Pro, 1.01; Lys, 0.97; Trp, 0.85.

EXAMPLE 5Preparation of cyclo(L-prolyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl)

5           The dried peptide, cyclo(L-prolyl-L-phenylal-  
anyl-D-tryptophyl-L-lysyl-O-benzyl-L-threonyl), is  
placed in a vessel suitable for HF cleavage. This  
vessel also contains a magnetic stirring bar. A small  
quantity of anisole sufficient to wet the peptide is  
added to this vessel. The vessel is next connected to  
10 an HF line and placed under vacuum to remove any air  
therein. The vessel is then cooled to about -78°C with  
a dry ice-acetone bath. Doubly distilled HF (about  
10 ml/gm of peptide) is added to the vessel. The dry  
ice-acetone bath is then removed from the vessel and  
replaced by an ice-water bath. The vessel's contents  
15 are vigorously stirred for about 45 minutes while the  
vessel remains immersed in the ice-water bath. Most of  
the HF in the vessel is then removed by water aspiration.  
After the majority of HF is removed by water aspiration,  
the remaining HF and anisole are removed via a vacuum  
20 pump to afford the title peptide.

25

30

35

EXAMPLE 6Evaluation of peptide effects on growth hormone, insulin, and glucagon release in mammals using the rat as the test species

5 In this evaluation, the procedures described by W. A. Murphy et al., Endocrinology, 109:491-495 (1980), were employed.

10 In growth hormone (GH) experiments, male rats (Charles Rivers) were anesthetized with NEMBUTAL® (5 mg per 100 g/BW) which also served to maintain stimulated plasma GH levels. Exactly 30 minutes after the rats were anesthetized, 0.5 ml of saline or the test peptide in saline was administered as a sc bolus. A 1 ml blood sample was drawn from the jugular vein 15 minutes after the injection. For examining blocking effects of the analog on somatostatin, the cyclic peptide was given 15 five minutes prior to somatostatin. GH levels were determined using NIADDKD rat GH RIA components.

Data obtained are reported in Table I below.

20

25

30

35

TABLE I

Effects of the Cyclic Pentapeptides, the Compounds of the Present Invention, Cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)] and the Unprotected Cyclo(Pro-Phe-D-Trp-Lys-Thr) Compared To Somatostatin on GH Levels in the Rat (Five Animals Per Group unless otherwise given).

	Peptide	Dose ( $\mu$ g/100 g body weight)	GH (ng/ml)*
10	A) Saline	-	389 $\pm$ 60 (6)
	B) Somatostatin	0.4	152 $\pm$ 51 (5)
	C) Cyclo(Pro-Phe-D-Trp-Lys-Thr)	2	730 $\pm$ 110 (6)
15	D) Cyclo(Pro-Phe-D-Trp-Lys-Thr)	10	459 $\pm$ 100 (5)
	C + B		75 $\pm$ 29 (5)
	D + B		114 $\pm$ 36 (4)
-----			
	A) Saline	-	648 $\pm$ 177
20	B) Cyclo(Pro-Phe-D-Trp-Lys-Thr)	0.3	1265 $\pm$ 318
	C) Cyclo(Pro-Phe-D-Trp-Lys-Thr)	0.6	1072 $\pm$ 187
	D) Cyclo(Pro-Phe-D-Trp-Lys-Thr)	1.2	728 $\pm$ 143
25	-----		
	A) Saline	-	497 $\pm$ 80
	B) Somatostatin	0.5	173 $\pm$ 46
	C) Cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)]	0.2	1724 $\pm$ 393
30	D) Cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)]	0.6	812 $\pm$ 163
	C + B		149 $\pm$ 73
	D + B		370 $\pm$ 73


\* = Mean  $\pm$  standard error (n).

From the above data, it can be seen that the compound of the present invention and an unprotected relative thereof were evaluated to determine the effects of both peptides on NEMBUTAL®-stimulated GH release in rats. Radioimmunoassayable GH levels in control-stimulated jugular blood  $648 \pm 177$  ng/ml showed an increase to  $1265 \pm 318$  after injection with  $0.3 \mu\text{g}/100$  g body weight of the unprotected analog cyclo(Pro-Phe-D-Trp-Lys-Thr); whereas, the radioimmunoassayable GH levels in control-stimulated jugular blood of  $497 \pm 80$  ng/ml rose significantly to  $1724 \pm 393$  ng/ml after injection of  $0.2 \text{ g}/100$  g body weight of the compound of the invention, i.e., the protected compound cyclo[Pro-Phe-D-Trp-Lys- Thr(Bzl)].


From the above data, it appears that the antagonist effect of the compounds of the present invention is not wholly dependent on the presence of the aromatic benzyl protecting group on the threonine.

## WHAT IS CLAIMED IS:

1. A cyclic pentapeptide compound having the structural formula:





wherein X is phenylalanyl, tyrosyl, tryptophyl, 4-chlorophenylalanyl, 4-bromophenylalanyl, 4-fluorophenylalanyl, 4-methoxyphenylalanyl, 4-benzyloxyphenylalanyl, 4-methylphenylalanyl, 5-fluorotryptophyl, 5-chlorotryptophyl, 5-bromotryptophyl, 5-methoxytryptophyl, 5-methyltryptophyl, histidyl or




Y is D-tryptophyl, D-5-fluorotryptophyl, D-5-bromotryptophyl, D-5-chlorotryptophyl, D-5-methoxytryptophyl, D-5-methyltryptophyl, D-phenylalanyl, D-4-chlorophenylalanyl, D-4-bromophenylalanyl, D-4-fluorophenylalanyl, D-4-methoxyphenylalanyl, D-4-benzyloxyphenylalanyl, D-4-methylphenylalanyl, D-tyrosyl or D-histidyl; Z is lysyl or arginyl; Thr is threonyl and R<sub>1</sub> is hydrogen, benzyl or substituted benzyl connected to the threonyl amino acid residue through its 3-oxygen atom; or a pharmaceutically acceptable salt thereof.


3. A compound according to Claim 1, cyclo[Pro-Phe-D-Trp-Lys-Thr(R<sub>1</sub>)] wherein R<sub>1</sub> is hydrogen or




5. A method for increasing release of growth hormone, insulin and glucagon, in mammals comprising administering thereto from 0.00001 to 1 mg/kg of mammalian body weight/day of a compound having the structural formula:



phenylalanyl, 4-methoxyphenylalanyl, 4-benzyloxyphenylalanyl, 4-methylphenylalanyl, 5-fluorotryptophyl, 5-chlorotryptophyl, 5-bromotryptophyl, 5-methoxytryptophyl, 5-methyltryptophyl, histidyl or



Y is D-tryptophyl, D-5-fluorotryptophyl, D-5-bromotryptophyl, D-5-chlorotryptophyl, D-5-methoxytryptophyl, D-5-methyltryptophyl, D-phenylalanyl, D-4-chlorophenylalanyl, D-5-bromophenylalanyl, D-4-fluorophenylalanyl, D-4-methoxyphenylalanyl, D-4-benzyloxyphenylalanyl, D-4-methylphenylalanyl, D-tyrosyl, or histidyl; Z is

lysyl or arginyl; R<sub>1</sub> is hydrogen or  $-\text{CH}_2-$   ;

R<sub>2</sub> is H, Cl, F, Br, I, C<sub>1</sub>-C<sub>4</sub> alkoxy or C<sub>1</sub>-C<sub>4</sub> alkyl; or pharmaceutically acceptable salts thereof.


6. A method according to Claim 5 for releasing growth hormone in mammals, wherein the compound administered to said mammalian host is cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)]; or cyclo(Pro-Phe-D-Trp-Lys-Thr).

7. A method according to Claim 5 for releasing insulin in mammals, wherein the compound administered to said mammalian host is cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)]; or cyclo(Pro-Phe-D-Trp-Lys-Thr).


8. A method according to Claim 5 for releasing glucagon in mammals, wherein the compound administered to said mammalian host is cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)]; or cyclo(Pro-Phe-D-Trp-Lys-Thr).



9. A method for the preparation of a cyclic pentapeptide compound having the structural formula:



wherein X is phenylalanyl, tyrosyl, tryptophyl, 4-chlorophenylalanyl, 4-bromophenylalanyl, 4-fluorophenylalanyl, 4-methoxyphenylalanyl, 4-benzyloxyphenylalanyl, 4-methylphenylalanyl, 5-fluorotryptophyl, 5-chlorotryptophyl, 5-bromotryptophyl, 5-methoxytryptophyl, 5-methyltryptophyl, histidyl or



Y is D-tryptophyl, D-5-fluorotryptophyl, D-5-bromotryptophyl, D-5-chlorotryptophyl, D-5-methoxytryptophyl, D-5-methyltryptophyl, D-phenylalanyl, D-4-chlorophenylalanyl, D-4-bromophenylalanyl, D-4-fluorophenylalanyl, D-4-methoxyphenylalanyl, D-4-benzyloxyphenylalanyl, D-4-methylphenylalanyl, D-tyrosyl or D-histidyl; Z is lysyl or arginyl; Thr is threonyl and R<sub>1</sub> is hydrogen, benzyl or substituted benzyl connected to the threonyl amino acid residue through its 3-oxygen atom; or a pharmaceutically acceptable salts thereof; said method characterized by reacting an amino acid protected by an α-amino acid protecting group, coupled to a resin with about 1% to 2% by weight, of a cross-linking agent.

10. A method according to Claim 9, wherein the amino acid protecters are t-butyloxycarbonyl, isopropylcarbonyl, diisopropyloxycarbonyl, benzyloxycarbonyl, cyclopentylonycarbonyl; the resin is polystyrene resin; and the cross-linking agent is divinyl benzene.



European Patent  
Office

**PARTIAL EUROPEAN SEARCH REPORT**  
which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

**0127899**

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 84106363.9
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
A	<p><u>EP - A1 - 0 029 310</u> (MERCK &amp; CO. INC.)</p> <p>* Claims 1,4,5,7; pages 6,7,9-13 *</p> <p>--</p>	1-4,9,10	<p>C 07 C 103/52</p> <p>A 61 K 37/02</p>
A	<p>NATURE, vol. 292, 1981</p> <p>D.F. VEBER et al. "A potent cyclic hexapeptide analogue of somato- statin", pages 55-58</p> <p>* Pages 56,57 *</p> <p>--</p>	1-4,9	
P,A	<p><u>EP - A2 - 0 104 348</u> (MERCK &amp; CO. INC.)</p> <p>* Claims 1,5,6; page 6,7,10-13 *</p> <p>----</p>	1-4,9,10	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 7)
			C 07 C 103/00
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-4,9,10</p> <p>Claims searched incompletely: --</p> <p>Claims not searched: 5-8</p> <p>Reason for the limitation of the search: Not searched as to methods for treatment of the human or animal body by therapy. Article 52(4) of the European Patent Convention.</p>			
Place of search VIENNA		Date of completion of the search 20-08-1984	Examiner PETROUSEK
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p> <p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published n, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>			

